11th Aug 2014 09:50
LONDON (Alliance News) - Biofrontera AG Monday said its licensee Perrigo Company PLC has filed a marketing approval dossier with Israel's Ministry of Health for Ameluz, its first prescription drug for the treatment of actinic keratosis.
Last week the European pharmaceutical company said that it has started selling Ameluz in Slovenia, the first of its Ameluz sales in the central eastern European region.
The company said Monday that after a preliminary review, the Israeli Ministry of Health accepted Ameluz for registration and issued a preliminary registration number, in order for a full review process to start.
With the acceptance of the dossier Biofrontera expects to obtain approval in Israel next year. It will market the drug under the same name.
Biofrontera, which specialises in the development of dermatological drugs, medical devices and medical cosmetics for the treatment of skin diseases, listed on London's AIM market in June.
Bionfrontera shares were quoted up 4.0% at 2.35 pence Monday morning.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L